



Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

May 28, 2014

CARMIEL, Israel, May 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference and the Wells Fargo Securities Research & Economics 2014 Healthcare Conference. Details regarding the conferences are as follows:

Jefferies 2014 Global Healthcare Conference

Monday, June 2, 2014 at 4:00 PM ET

The Grand Hyatt, New York, NY

Wells Fargo Securities Research & Economics 2014 Healthcare Conference

Tuesday, June 17, 2014 at 2:55 PM ET

The Boston Intercontinental Hotel, Boston, MA

A live webcast of each presentation will be available at www.protalix.com on the event calendar page and a replay of each conference will be archived and available after the respective conference for 30 days.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx[®]. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, by the Australian Therapeutic Goods Administration (TGA) in May 2014 and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel[®]) for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, colitis, psoriasis and other autoimmune and inflammatory disorders; PRX-110 for the treatment of Cystic Fibrosis; and others.

CONTACT: Investor Contact

Tricia Truehart

The Trout Group, LLC

646-378-2953

ttruehart@troutgroup.com

Media Contact

Kari Watson

MacDougall Biomedical Communications

781-235-3060

kwatson@macbiocom.com

Protalix BioTherapeutics, Inc.